Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.43 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14059590 | 0.87 | ERN1 (0.48) | ERN1SLC6A2SLC6A4ALDH1A1CYP2C9 | |
| SCHEMBL6409033 | 0.82 | CYP2C9 (0.66) | SLC6A2SLC6A4ALDH1A1CYP2C9CYP2C19 | |
| SCHEMBL29948203 | 0.81 | CA1 (0.67) | ALDH1A1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL130793 | 0.81 | CA1 (0.67) | ALDH1A1CYP2C9CYP2C19CYP1A2CYP3A4 | |
| SCHEMBL12775737 | 0.79 | MAPK1 (0.57) | ERN1ALDH1A1CYP2C9CYP2C19CYP1A2 | |
| SCHEMBL30740888 | 0.79 | MAPT (0.60) | ERN1ALDH1A1CYP2C9CYP2C19HPGD | |
| SCHEMBL1808835 | 0.79 | MAPT (0.60) | ERN1ALDH1A1CYP2C9CYP2C19HPGD | |
| SCHEMBL12062763 | 0.79 | TAS1R3 (0.49) | ERN1SLC6A2SLC6A4ALDH1A1CYP2C9 | |
| SCHEMBL11702564 | 0.78 | ALDH1A1 (0.69) | ERN1SLC6A2SLC6A4ALDH1A1CYP2C9 | |
| SCHEMBL8325433 | 0.78 | HTT (0.67) | ERN1SLC6A2SLC6A4ALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3272754-B1 | IMIDAZOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2019-05-29 | — | — | EP | disclosed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884828-B2 | Substituted cinnolines as inhibitors of LRRK2 kinase activity | IMAGO PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-3272754-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2018-01-24 | — | — | EP | disclosed |
| EP-2855483-B1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| EP-2948451-B1 | SUBSTITUTED PURINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-07-12 | — | — | EP | disclosed |
| EP-2948451-B1 | SUBSTITUTED PURINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-07-12 | — | — | EP | disclosed |
| EP-3064502-A1 | IMIDAZOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2016-09-07 | — | — | EP | disclosed |
| US-9403827-B2 | Substituted purinone compounds | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-9403827-B2 | Substituted purinone compounds | NOVARTIS AG (CH) | 2016-08-02 | — | — | US | disclosed |
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | NAKAMURA YOSHINORI | 2011-04-21 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-7906517-B2 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-03-15 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090029994-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090023729-A1 | Trisubstituted amine compound | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-01-22 | — | — | US | disclosed |
| EP-1979331-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| EP-1979341-A1 | TRISUBSTITUTED AMINE COMPOUND | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-10-15 | — | — | EP | disclosed |
| WO-2007088996-A1 | TRISUBSTITUTED AMINE COMPOUNDS AS INHIBITORS OF -CHOLESTERYL ESTER TRANSFER PROTEIN CETP | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
| WO-2007088999-A1 | TRISUBSTITUTED AMINE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092506-A1 | TRISUBSTITUTED AMINE COMPOUND | CETP, MTTP, APOB | ERN1 968/4885SLC6A2 1191/4885SLC6A4 1347/4885 |
| US-20090029994-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | ERN1 968/4885SLC6A2 1191/4885SLC6A4 1347/4885 |
| US-20090023729-A1 | Trisubstituted amine compound | CETP, MTTP, APOB | ERN1 992/4885SLC6A2 1359/4885SLC6A4 1594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.